Published • loading... • Updated
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
Summary by The Caledonian Record
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Ibrance's would-be successors, the data that helped sell Tubulis to Gilead, and more at ASCO
All of the regular ASCO abstracts dropped Thursday afternoon. Find updates on potential successors for Pfizer’s blockbuster Ibrance, the Tubulis data that got Gilead Sciences excited enough to buy it out and more.
Gilead Sciences acquires Tubulis for $5bn
First announced last month, the move aims to advance Gilead’s oncology portfolio. Under the agreement, the company acquired all outstanding equity of Tubulis for $3.15bn upfront on a The post Gilead Sciences acquires Tubulis for $5bn appeared first on Pharmaceutical Business review.
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
